Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

Cullinan Therapeutics (CGEM) announced new clinical data from its Phase 1 study of CLN-049, a novel, investigational FLT3xCD3 bispecific T cell engager, in patients with relapsed/refractory acute ...

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Myelodysplastic syndromes are a complex and heterogenous group of clonal myeloid neoplasms, characterised by ineffective ...

Justin Watts, MD, associate professor in the hematology division at Sylvester Comprehensive Cancer Center and part of the ...

(MENAFN- GlobeNewsWire - Nasdaq) Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell Therapy ...

HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...

Dr. Zaker Schwabkey is a physician and an Assistant Professor of Medicine and Clinical Investigator in the Division of Hematology & Hematologic Malignancies at the University of Utah’s Huntsman Cancer ...

Luke Fletcher, MD, reviews updates in anemia-predominant MDS and the 2025 polling results from MDS Case-Based Roundtable events. Myelodysplastic syndrome (MDS) is a heterogeneous clonal hematologic ...

MNV-201, a mitochondrial cell therapy, received FDA fast track designation for myelodysplastic syndrome, highlighting its potential to address mitochondrial dysfunction in this serious blood disorder.